Biogen labs announced that their new drug called Aducanumab, designed to get rid of beta-amyloid plaques, met or exceeded expectations in a small Phase 1 trial. Compared to the placebo group who worsened by 3.14 points over the course of a year on a 30-point scale, the experimental group who received the highest dosage declined only .58 points. Reported in the Business Section, New York Times, March 20, 2015. (If these results are replicated, this will be the first Alzheimer’s drug to be truly effective, CV).
Posted March 20